Eines der Hauptziele von Life4me+ — ist neue Fälle von HIV und anderen STIs, Hepatitis C und Tuberkulose zu verhindern.

Die App hilft, eine Kommunikation zwischen Ärzten und HIV-positiven Menschen aufzubauen. Die App erlaubt Ihnen, einen Zeitplan für Ihre Medikamenteneinnahme bequem zu organisieren – dies geschieht über eine für Dritte nicht nachvollziehbare und personalisierte Erinnerung.

5846

Specialized clinical information about coronavirus COVID-19

The situation is rapidly evolving, and information is being constantly updated. Last updated

View FAQs about COVID-19 and people living with HIV

View FAQs
Updates on coronavirus disease (COVID-19) pandemic
Q&A on coronavirus (COVID-19)
Coronavirus Innovation Map
Show more Show less
Rights in the time of COVID-19. Lessons from HIV for an effective, community-led response.
What People Living with HIV Need to Know about HIV and COVID-19
COVID-19 infection questionnaire for persons living with HIV
Life in the time of COVID-19
EACS & BHIVA Statement on risk of COVID-19 for people living with HIV (PLWH)
Special CROI-2020 session on COVID-19
Drug interactions with experimental COVID-19 therapies.
Detailed recommendations for interactions with experimental COVID-19 therapies.
At-a-glance summary of interactions with experimental COVID-19 therapies.
Administration in cases of swallowing difficulties.
Evaluating the interaction risk of experimental COVID-19 therapies.
SARS-CoV-2 - Specific antiviral Treatment (preliminary document)
Show more Show less
Interim clinical guidance for patients suspected of/confirmed with COVID-19 in Belgium
Inpatient guidance for treatment of COVID-19 in adults and children (University of Michigan, USA)
Руководство по лечению и поддерживающей терапии пациентов с коронавирусной инфекцией COVID-19 (Италия, Ломбардия)
Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) (Released by National Health Commission & State Administration of Traditional Chinese Medicine)
SOLIDARITY - WHO launches global megatrial of the four most promising coronavirus treatments
A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence
Show more Show less
Therapeutic options for the 2019 novel coronavirus (2019-nCoV) in Nature Reviews
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
Show more Show less
BCG vaccination to Reduce the impact of COVID-19 in Australian healthcare workers following Coronavirus Exposure (BRACE) Trial
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection (in USA)
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Show more Show less
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.
Show more Show less
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.
Show more Show less
Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR.
Show more Show less
A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)
A Prospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
Clinical Controlled Trial for Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)
A real-world study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19)
A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)
Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Show more Show less
A randomized, open label, parallel controlled trial of evaluating the efficacy of recombinant cytokine gene-derived protein injection for clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)
A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection
EATG (European Aids Treatment Group) statement on the evolving COVID-19 pandemic
The Position of Correlation-European Harm Reduction Network and EHRA on the Continuity of Harm Reduction Services During the COVID-19 Crisis
Human Rights Dimensions of COVID-19 Response
COVID-19: Sex Workers Need Immediate Financial Support and Protection
COVID19: “Staying Home” Not an Option for People Experiencing Homelessness
Coronavirus: Healthcare and human rights of people in prison

View FAQs about COVID-19 and people living with HIV

View FAQs

If you have questions or comments about HIV and COVID-19, let us know [email protected]